Human β-defensin 3 (DEFB103) and its influence on Staphylococcus aureus nasal carriage

International Journal of Infectious Diseases

Volumn 15, Issue 6, 2011, Pages

  Fode, Peder ^a   Stegger, Marc ^a   Andersen, Paal Skytt ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Copy number variation; Human beta defensin 3; Pyrosequencing based paralog ratio test; Staphylococcus aureus

Indexed keywords

BETA DEFENSIN 3; MESSENGER RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DEFB103 GENE; DISEASE CARRIER; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; NORMAL HUMAN; NOSE SMEAR; REAL TIME POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS;

ADULT; AGED; AGED, 80 AND OVER; BETA-DEFENSINS; CARRIER STATE; FEMALE; GENE DOSAGE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; NASAL CAVITY; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79955963079     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.02.003     Document Type: Article

References (65)

1. Boman H.G. Innate immunity and the normal microflora. Immunol Rev 2000, 173:5-16.
2. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710-720.
3. Lehrer R.I. Primate defensins. Nat Rev Microbiol 2004, 2:727-738.
4. Bulet P., Stocklin R., Menin L. Anti-microbial peptides: from invertebrates to vertebrates. Immunol Rev 2004, 198:169-184.
5. Schutte B.C., Mitros J.P., Bartlett J.A., Walters J.D., Jia H.P., Welsh M.J., et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A 2002, 99:2129-2133.
6. Ganz T., Lehrer R.I., Defensins Curr Opin Immunol 1994, 6:584-589.
7. Lehrer R.I., Ganz T. Defensins: endogenous antibiotic peptides from human leukocytes. Ciba Found Symp 1992, 171:276-290.
8. Lehrer R.I., Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002, 14:96-102.
9. Selsted M.E., Harwig S.S., Ganz T., Schilling J.W., Lehrer R.I. Primary structures of three human neutrophil defensins. J Clin Invest 1985, 76:1436-1439.
10. Ganz T., Selsted M.E., Szklarek D., Harwig S.S., Daher K., Bainton D.F., et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985, 76:1427-1435.
11. Jones D.E., Bevins C.L. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992, 267:23216-23225.
12. Fulton C., Anderson G.M., Zasloff M., Bull R., Quinn A.G. Expression of natural peptide antibiotics in human skin. Lancet 1997, 350:1750-1751.
13. Harder J., Bartels J., Christophers E., Schroder J.M. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001, 276:5707-5713.
14. Garcia J.R., Jaumann F., Schulz S., Krause A., Rodriguez-Jimenez J., Forssmann U., et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001, 306:257-264.
15. Harder J., Bartels J., Christophers E., Schroder J.M. A peptide antibiotic from human skin. Nature 1997, 387:861.
16. Bals R., Wang X., Wu Z., Freeman T., Bafna V., Zasloff M., et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998, 102:874-880.
17. Jin G., Kawsar H.I., Hirsch S.A., Zeng C., Jia X., Feng Z., et al. An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One 2010, 5:e10993.
18. Semple F., Webb S., Li H.N., Patel H.B., Perretti M., Jackson I.J., et al. Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 2010, 40:1073-1078.
19. Yang D., Chertov O., Bykovskaia S.N., Chen Q., Buffo M.J., Shogan J., et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528.
20. Linzmeier R., Ho C.H., Hoang B.V., Ganz T. A 450-kb contig of defensin genes on human chromosome 8p23. Gene 1999, 233:205-211.
21. Hollox E.J., Armour J.A., Barber J.C. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003, 73:591-600.
22. Hollox E.J., Huffmeier U., Zeeuwen P.L., Palla R., Lascorz J., Rodijk-Olthuis D., et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008, 40:23-25.
23. Fellermann K., Stange D.E., Schaeffeler E., Schmalzl H., Wehkamp J., Bevins C.L., et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006, 79:439-448.
24. Bentley R.W., Pearson J., Gearry R.B., Barclay M.L., McKinney C., Merriman T.R., et al. Association of higher DEFB4 genomic copy number with Crohn's disease. Am J Gastroenterol 2010, 105:354-359.
25. Janssens W., Nuytten H., Dupont L.J., Van Eldere J., Vermeire S., Lambrechts D., et al. Genomic copy number determines functional expression of β-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182:163-169.
26. Jansen P.A., Rodijk-Olthuis D., Hollox E.J., Kamsteeg M., Tjabringa G.S., de Jongh G.J., et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009, 4:e4725.
27. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
28. Kluytmans J., van Belkum A., Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10:505-520.
29. Williams R.E. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963, 27:56-71.
30. Armstrong-Esther C.A. Carriage patterns of Staphylococcus aureus in a healthy non-hospital population of adults and children. Ann Hum Biol 1976, 3:221-227.
31. Hoffler U., Bulanda M., Heczko P.B., Pulverer G. A comparison of staphylococcal nasal carrier rates in Germany and Poland. Med Microbiol Immunol 1978, 164:285-290.
32. Maxwell J.G., Ford C.R., Peterson D.E., Mitchell C.R. Long-term study of nasal staphylococci among hospital personnel. Am J Surg 1969, 118:849-854.
33. Cole A.M., Tahk S., Oren A., Yoshioka D., Kim Y.H., Park A., et al. Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol 2001, 8:1064-1069.
34. Peacock S.J., Justice A., Griffiths D., de Silva G.D., Kantzanou M.N., Crook D., et al. Determinants of acquisition and carriage of Staphylococcus aureus in infancy. J Clin Microbiol 2003, 41:5718-5725.
35. Yu V.L., Goetz A., Wagener M., Smith P.B., Rihs J.D., Hanchett J., et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986, 315:91-96.
36. Lipsky B.A., Pecoraro R.E., Chen M.S., Koepsell T.D. Factors affecting staphylococcal colonization among NIDDM outpatients. Diabetes Care 1987, 10:483-486.
37. von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001, 344:11-16.
38. Wertheim H.F., Vos M.C., Ott A., van Belkum A., Voss A., Kluytmans J.A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364:703-705.
39. Nouwen J.L., Fieren M.W., Snijders S., Verbrugh H.A., van Belkum A. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int 2005, 67:1084-1092.
40. van Belkum A., Verkaik N.J., de Vogel C.P., Boelens H.A., Verveer J., Nouwen J.L., et al. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis 2009, 199:1820-1826.
41. Vandenbergh M.F., Yzerman E.P., van Belkum A., Boelens H.A., Sijmons M., Verbrugh H.A. Follow-up of Staphylococcus aureus nasal carriage after 8years: redefining the persistent carrier state. J Clin Microbiol 1999, 37:3133-3140.
42. Corrigan R.M., Rigby D., Handley P., Foster T.J. The role of Staphylococcus aureus surface protein SasG in adherence and biofilm formation. Microbiology 2007, 153:2435-2446.
43. Corrigan R.M., Miajlovic H., Foster T.J. Surface proteins that promote adherence of Staphylococcus aureus to human desquamated nasal epithelial cells. BMC Microbiol 2009, 9:22.
44. Weidenmaier C., Kokai-Kun J.F., Kristian S.A., Chanturiya T., Kalbacher H., Gross M., et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004, 10:243-245.
45. Noble W.C. Carriage of Staphylococcus aureus and beta haemolytic streptococci in relation to race. Acta Derm Venereol 1974, 54:403-405.
46. Noble W.C., Valkenburg H.A., Wolters C.H. Carriage of Staphylococcus aureus in random samples of a normal population. J Hyg (Lond) 1967, 65:567-573.
47. Cole A.M., Dewan P., Ganz T. Innate antimicrobial activity of nasal secretions. Infect Immun 1999, 67:3267-3275.
48. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299:2076-2079.
49. von B.H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321:691-696.
50. van den Akker E.L., Nouwen J.L., Melles D.C., van Rossum E.F., Koper J.W., Uitterlinden A.G., et al. Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J Infect Dis 2006, 194:814-818.
51. Emonts M., Uitterlinden A.G., Nouwen J.L., Kardys I., Maat M.P., Melles D.C., et al. Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J Infect Dis 2008, 197:1244-1253.
52. Nouwen J.L., Ott A., Kluytmans-Vandenbergh M.F., Boelens H.A., Hofman A., van B.A., et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a 'culture rule'. Clin Infect Dis 2004, 39:806-811.
53. Armour J.A., Palla R., Zeeuwen P.L., den Heijer M., Schalkwijk J., Hollox E.J. Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats. Nucleic Acids Res 2007, 35:e19.
54. Aldhous M.C., Abu Baker S., Prescott N.J., Palla R., Soo K., Mansfield J.C., et al. Measurement methods and accuracy in copy number variation: failure to replicate associations of beta-defensin copy number with Crohn's disease. Hum Mol Genet 2010, 19:4930-4938.
55. Groth M., Szafranski K., Taudien S., Huse K., Mueller O., Rosenstiel P., et al. High-resolution mapping of the 8p23.1 beta-defensin cluster reveals strictly concordant copy number variation of all genes. Hum Mutat 2008, 29:1247-1254.
56. Perne A., Zhang X., Lehmann L., Groth M., Stuber F., Book M. Comparison of multiplex ligation-dependent probe amplification and real-time PCR accuracy for gene copy number quantification using the beta-defensin locus. Biotechniques 2009, 47:1023-1028.
57. Wertheim H.F., Melles D.C., Vos M.C., van Leeuwen W., van Belkum A., Verbrugh H.A., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005, 5:751-762.
58. Eriksen N.H., Espersen F., Rosdahl V.T., Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 1995, 115:51-60.
59. Larsen A.R., Goering R., Stegger M., Lindsay J.A., Gould K.A., Hinds J., et al. Two distinct clones of methicillin-resistant Staphylococcus aureus (MRSA) with the same USA300 pulsed-field gel electrophoresis profile: a potential pitfall for identification of USA300 community-associated MRSA. J Clin Microbiol 2009, 47:3765-3768.
60. Grundmann H., Aanensen D.M., van den Wijngaard C.C., Spratt B.G., Harmsen D., Friedrich A.W. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med 2010, 7:e1000215.
61. Hollox E.J. Copy number variation of beta-defensins and relevance to disease. Cytogenet Genome Res 2008, 123:148-155.
62. Chen P.H., Fang S.Y. Expression of human beta-defensin 2 in human nasal mucosa. Eur Arch Otorhinolaryngol 2004, 261:238-241.
63. Dauletbaev N., Gropp R., Frye M., Loitsch S., Wagner T.O., Bargon J. Expression of human beta defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold. Respiration 2002, 69:46-51.
64. Joly S., Organ C.C., Johnson G.K., McCray P.B., Guthmiller J.M. Correlation between beta-defensin expression and induction profiles in gingival keratinocytes. Mol Immunol 2005, 42:1073-1084.
65. Groth M., Wiegand C., Szafranski K., Huse K., Kramer M., Rosenstiel P., et al. Both copy number and sequence variations affect expression of human DEFB4. Genes Immun 2010, 11:458-466.